Navigation Links
Boston Scientific Announces Global Launch of Journey™ Guidewire
Date:10/13/2010

NATICK, Mass., Oct. 13 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Journey™ Guidewire, an innovative 0.014" guidewire designed for use in challenging, small vessel peripheral angioplasty procedures.  The Journey Guidewire strengthens Boston Scientific's broad portfolio of devices designed to address physician needs in treating arteries below the knee.  

James Benenati, M.D., Medical Director of the Baptist Cardiac and Vascular Institute in Miami, and President of the Society of Interventional Radiology, has performed some of the initial procedures using the new Journey Guidewire, including a live case at the recent Transcatheter Cardiovascular Therapeutics scientific symposium.

"In my experience, the Journey Guidewire provides exceptional torque and flexibility, particularly in difficult cases involving small vessels or tortuous anatomy," said Dr. Benenati.  "This highly durable guidewire offers outstanding precision and tracking to help access the toughest peripheral lesions."

Guidewires are thin, flexible wires used to facilitate the placement of balloon catheters or other therapeutic devices.  The Journey Guidewire builds on Boston Scientific's advanced guidewire technology used in coronary and neurovascular interventions.  It features a micro-cut nitinol sleeve designed to provide efficient transmission of torque energy for more precise turn-by-turn response and control compared to conventional spring-coil guidewires.  The nitinol distal core and hydrophilic coating are designed to enhance wire durability, tactile response and device delivery for improved overall performance.

"The Journey Guidewire reflects Boston Scientific's commitment to providing physicians the most advanced solutions for peripheral interventions," said Joe Fitzgerald, Senior Vice President and President of Boston Scientific's Endovascular Unit.  "Journey enhances our below-the-knee portfolio, which includes a number of leading products to treat this challenging anatomy."  

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.CONTACT:

Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific Corporation
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
2. Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy
3. Boston Scientifics TAXUS® Element™ Stent Demonstrates Strong Outcomes in Diabetic Patients
4. Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element™ Stent
5. Boston Scientific to Acquire Asthmatx
6. Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds
7. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
8. Boston Millennia Partners Portfolio Company CardioMEMS Signs Equity Investment and Exclusive Option to be Acquired for an Additional $375,000,000
9. Childrens Hospital Boston and Particle Sciences Cooperate on Translational Medicine Efforts
10. Boston Scientifics Womens Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association
11. Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 194 Mitgliedsstaaten ... Eliminierung von viraler Hepatitis    Am ... eingegangen, virale Hepatitis bis 2030 zu eliminieren. ... Assembly haben sich die Staaten einstimmig dafür entschieden, ... Viral Hepatitis Strategy) zu verabschieden, was das bisher ...
(Date:5/30/2016)... , May 30, 2016 ... "Healthcare Analytical Testing Services Market by Type (Stability, ... Services), by End User (Pharmaceutical Companies, Medical Device ... MarketsandMarkets, The market witnessed healthy growth during the ... a CAGR of 11.3% between 2016 and 2021 ...
(Date:5/30/2016)... , May 30, 2016 ... 2016" market research report with comprehensive information on ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 31, 2016 , ... Spartan Bioscience today introduced the Spartan ... convenience. , The Cube is exceptionally small—it takes up the space of a ... into any space, whether in a hospital, doctor’s office, or pharmacy. , The ...
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, ... know – London is home to Ontario’s leading day spa and one of Canada’s ... Tamba began with a unique concept to combine spa services with hair and ...
(Date:5/31/2016)... ... ... In his latest video, renowned AstroNumerologist Jesse Kalsi reveals ... candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys the ... numbers up,” says Kalsi. “It is about looking at each individual number, since ...
(Date:5/31/2016)... ... 31, 2016 , ... Interest is on the rise for using the CRISPR-Cas9 ... tool for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with ... CRISPR RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens ...
(Date:5/31/2016)... ... , ... In a recent interview on The Greenburgh Report radio show hosted ... WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed several eye-opening ... maelstrom.” , During the interview with Mr. Feiner that aired on May 7, ...
Breaking Medicine News(10 mins):